Apoptosis induced by nucleosides in the human hepatoma HepG2

Table 2 Effects of nucleosides on the cell cycle progression, caspas-3 activity and sFas-L content in HepG2 cells¹

Treatment	Control	Inosine	Cytidine	Uridine	Thymidine	Adenosine	Gaunosine
SubG1 (%)	2.6±0.8a	3.2±0.3a	6.9±0.2a	6.5±1.5a	26.8±2.3a	9.6±1.5a	5.7±1.2a
G0/G1(%)	67.7±1.1a	69.2±0.1a	74.1±1.3a	84.8±2.6a	54.4±1.8a	64.8±1.4a	68.0±1.9a
S (%)	15.7±0.0a	18.8±0.3a	8.5±0.2a	3.1±0.3a	12.0±0.2a	10.6±0.4a	17.3±0.7a
G2/M (%)	14.0±1.9a	8.8±0.1a	10.5±1.0a	5.7±0.8a	6.8±0.8a	15.0±0.9a	9.0±1.3a
Caspase-3 (%)2	100±0a	101±5a	97±6a	98±5a	148±2a	104±4a	100±3a
sFas-L (pg/mL)	0.11±0.01a	0.14±0.01a	0.08±0.03a	0.15±0.03a	0.17±0.02a	0.15±0.07a	0.10±0.03a

¹Cells were treated with or without nucleosides for 12 h. The contents of inosine, cytidine, uridine, and thymidine in the mediums were 30 mmol/L, respectively, and, the contents of adenosine and guanosine were 0.5 mmol/L. Values are expressed as the mean±SD of four independent experiments.

^aP<0.05 vs others.

²Caspase-3 activity was shown as percentage to compare with control group.